Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2401 - 2425 of 15169 in total

Vespula maculifrons venom protein

Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Turoctocog alfa pegol

Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. ... The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a ... rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Simethicone

Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … Gelusil Antacid and Anti-gas …

Atezolizumab

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Durvalumab

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Avelumab

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … ] and Health Canada,[L48171] respectively. ... programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Givosiran

Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States ... genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and ... non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Pitolisant

Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Description: … [L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized ... [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and ... treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and …

Milk thistle

Milk thistle is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Investigational
Matched Categories: … Herbs and Natural Products …

Nilutamide

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … the growth of normal and malignant prostatic tissue. ... Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Zaleplon

Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Approved
Illicit
Investigational
Matched Description: … Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Miscellaneous Anxiolytics Sedatives and Hypnotics …

Padeliporfin

Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. Padeliporfin...
Approved
Experimental
Matched Description: … Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Oxeladin

Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Matched Description: … Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. …
Matched Categories: … Cough and Cold Preparations …

Fanolesomab

Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …

Cedazuridine

Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated.[A215082, A215092, A215097] Hypomethylating agents such as decitabine and azacitidine are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous...
Approved
Investigational
Matched Description: … treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells. ... [A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to ... [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Digoxin Immune Fab (Ovine)

Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …

Polistes fuscatus venom protein

Polistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Ibrutinib

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Description: … It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies ... [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 ... [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Calcium alginate

Approved
Experimental
Matched Categories: … Blood and Blood Forming Organs …

Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Iupac: … (6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro …
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and ... [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and …

Peanut oil

Peanut oil is derived from Arachis hypogaea which can be found in South America, Mexico, and Centro America. The kernels are consumed roasted but a large percentage is used for the production of vegetable oil. The peanut oil represents about 45-52% of the kernel content and it is mainly formed...
Approved
Matched Description: … Peanut oil is derived from _Arachis hypogaea_ which can be found in South America, Mexico, and Centro ... The peanut oil represents about 45-52% of the kernel content and it is mainly formed from monounsaturated …
Matched Categories: … Basic Ointments and Protectants …

Celiprolol

Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina ... It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 …

Upadacitinib

Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage...
Approved
Investigational
Matched Description: … and bone destruction, leading to co-morbidities. ... Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic ... It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Abatacept

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Karaya gum

Karaya gum allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Equipment and Supplies ... Alimentary Tract and Metabolism …
Displaying drugs 2401 - 2425 of 15169 in total